We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CHILE:BCSBanco de Chile Analysis

Data as of 2026-06-07 - not real-time

$75.43

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Sociedad Química y Minera de Chile (SQM) trades at $75.43, well below its DCF fair value of $212, indicating a substantial undervaluation (undervalued) despite a 40% 30‑day volatility and a beta of 1.30, which suggest a higher risk profile. The stock sits just above its calculated support of $74.63 and is approaching the 20‑day SMA of 83.82, while the 14‑day RSI of 33.9 points to oversold conditions that could spark a short‑term rebound. However, the MACD histogram remains negative (-0.87) and the MACD line is below the signal line, signaling lingering bearish momentum in the near term. On the fundamentals side, SQM posted a 69.8% revenue growth year‑over‑year, a healthy operating margin of 41%, and free cash flow exceeding $1.7 bn, supporting a sustainable dividend yield of 1.36% with a zero payout ratio. The company’s exposure to lithium—critical for EV batteries—combined with its diversified specialty chemicals business positions it as a growth play in a sector benefiting from secular demand trends. Analyst consensus remains bullish (12‑month median target $82) and the “Extreme Greed” market sentiment (fear‑greed index 83) further underscores the upside potential.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in oversold territory suggests a possible bounce
  • Bearish MACD histogram indicates continued downside pressure
  • Proximity to technical support reduces downside risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF valuation shows >8% upside
  • Strong revenue growth and high operating margins
  • Lithium market tailwinds driving earnings expansion

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Secular demand for lithium in EV batteries
  • Robust free cash flow supporting dividend sustainability
  • Significant valuation gap between market price and intrinsic value

Key Metrics & Analysis

Financial Health

Revenue Growth69.80%
Profit Margin15.38%
P/E Ratio26.4
ROE13.40%
ROA7.20%
Debt/Equity63.39
P/B Ratio3.7
Op. Cash Flow$2.0B
Free Cash Flow$1.7B

Technical Analysis

TrendNeutral
RSI33.9
Support$74.63
Resistance$95.74
MA 20$83.82
MA 50$85.56
MA 200$67.03
MACDBearish
VolumeIncreasing
Fear & Greed Index83.02

Valuation

Fair Value$212.15
Target Price$82.16
Upside/Downside8.93%
GradeUndervalued
TypeGrowth
Dividend Yield1.36%

Risk Assessment

Beta1.30
Volatility40.24%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.